Fundraising Fox
GID BIO
Louisville, US · Delaware corporation · 1 known investors
Find your way into GID BIO
Each arrow is one introduction. Sign up to fill in the first one.
43 people can intro you to Dwight
Ask Ann O'Connor to introduce you to Dwight Zurawski
You →Ann · together at McKinley Medical →Dwight
36 people can intro you to David
Ask Jamie Chen to introduce you to David Springer
You →Jamie · together at Verve Medical, Inc. →David
Sign up to find every way you can get introduced to GID BIO
- Your email: who you already know at GID BIO, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the GID BIO team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
GID BIO develops investigational adipose-derived cell therapies and device platforms aimed at offering physicians and patients alternatives between short-term relief and major surgery. The company operates in the regenerative medicine and medical device space.
Founders & leadership
WW
William W CiminioCo-founder
DS
David SpringerFounder, Board of DirectorsDavid Springer has led commercial and early-stage medical device and digital health companies for over three decades, serving as CEO of Cayenne Medical and CHF Solutions (acquired by Zimmer Biomet and Gambro), COO of Sharecare, and senior executive at WebMD and St. Jude Medical. He holds a Bachelor of Science in Industrial Management from Purdue University.
DZ
Dwight ZurawskiChief Financial OfficerHe has experience in financial accounting and tax matters across healthcare, manufacturing, distribution, construction, and oil & gas sectors, with expertise in FDA quality systems and business expansion.
WC
William CiminoNamed on SEC filing
NP
Nicholas PachudaNamed on SEC filing
WF
William FutrellNamed on SEC filing
MS
Morgan St. JohnNamed on SEC filing
JM
John MarousNamed on SEC filing
RB
Roy BostockNamed on SEC filing
AK
Adam KatzFounder, Board of Directors
DS
David S. SmithNamed on SEC filing
Investors · 1
Also in the syndicate · 1
The Richard King Mellon Foundation
Funding
SEC filings, press & company announcements$7.7M disclosed across 3 rounds · 2013–2021
- $250KraisedAug 2020 · 2 sources
The Richard King Mellon Foundation
Source ↗
▶$5.3MraisedJan 2022 · 27 investors · Other Health CareRule 506(b)
▶$5.3MraisedJan 2022 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William CiminoExecutive Officer, Director
- Nicholas PachudaDirector
- William FutrellDirector
- Morgan St. JohnDirector
- John MarousDirector
- Roy BostockDirector
- Adam KatzDirector
- David S. SmithExecutive Officer
- Amount sold
- $5.3M
- Minimum investment
- $50K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedJan 2014 · 18 investors · Other Health CareRule 506(b)
▶$2.2MraisedJan 2014 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jesse SheffermanDirector
- David S SmithExecutive Officer
- J. William FutrellExecutive Officer, Director
- Carlos PellasDirector
- Morgan St. JohnDirector
- William W CiminioExecutive Officer, Director
- Adam KatzDirector
- Ruben DiazDirector
- Offering amount
- $3M
- Amount sold
- $2.2M
- Minimum investment
- $25K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
Gate BioGate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.
GentiBioGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Ligo BiosciencesLigo develops computational tools for enzyme design by combining large language models with specialized neural networks to enable scientists and AI agents to discover new enzymes and biological functions.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Forge BiologicsForge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure. It supports gene therapy developers across early development, clinical trials, and commercial production, and is a subsidiary of the Ajinomoto Group.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Gain TherapeuticsGain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
Companies working in the same space as GID BIO.
In the news
Frequently asked questions
- What does GID BIO do?
- GID BIO develops investigational adipose-derived cell therapies and device platforms aimed at offering physicians and patients alternatives between short-term relief and major surgery. The company operates in the regenerative medicine and medical device space.
- Who founded GID BIO?
- GID BIO was founded by J. William Futrell, William W Ciminio, David Springer.
- How much funding has GID BIO raised?
- GID BIO has disclosed $7.7M raised across 3 rounds.
- Where is GID BIO headquartered?
- GID BIO is headquartered in Louisville, US.